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Breast cancer affects one in eight women making it the most common cancer in
the United Kingdom, accounting for 15% of all new cancer cases. One of the main
challenges in treating breast cancer is the heterogeneous nature of the disease. At
present, targeted therapies are available for hormone receptor- and HER2-positive
tumors. However, no targeted therapies are currently available for patients with triple
negative breast cancer (TNBC). This likely contributes to the poor prognostic outcome
for TNBC patients. Consequently, there is a clear clinical need for the development
of novel drugs that efficiently target TNBC. Extensive genomic and transcriptomic
characterization of TNBC has in recent years identified a plethora of putative oncogenes.
However, these driver oncogenes are often critical in other cell types and/or transcription
factors making them very difficult to target directly. Therefore, other approaches may
be required for developing novel therapeutics that fully exploit the specific functions of
TNBC oncogenes in tumor cells. Here, we will argue that more research is needed
to identify the protein-protein interactions of TNBC oncogenes as a means for (a)
mechanistically understanding the biological function of these oncogenes in TNBC and
(b) providing novel therapeutic targets that can be exploited for selectively inhibiting the
oncogenic roles of TNBC oncogenes in cancer cells, whilst sparing normal healthy cells.
Keywords: transcription factor, breast cancer, TNBC, protein-protein interaction, protein complexes, cancer
therapy, PROTAC, post-translational modification
BREAST CANCER SUBTYPES AND ASSOCIATED THERAPIES
Breast cancer is the most common cancer in the United Kingdom, accounting for 15% of all
new cancer cases, and is the leading cause of cancer death in women worldwide (Bray et al.,
2018). Historically, breast cancers have been classified based on the expression of several cell-
surface receptors, namely the estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) (Onitilo et al., 2009). Based on the presence or absence
of these markers, breast cancers can be broadly stratified into luminal A/B, HER2+, or basal-like
(triple-negative) subtypes. Specifically, luminal A/B breast cancers are characterized as hormone
receptor positive (high expression of ER and/or PR); HER2+ breast cancers are characterized
by amplification of HER2 (and can be ER+ and/or PR+); and triple negative breast cancers
(TNBCs) are characterized as hormone receptor negative and HER2 negative (ER−/PR−/HER2−)
(Onitilo et al., 2009). Receptor status continues to act as a critical assessment for all breast cancers,
likely due to the quick, easy and cost-effective stratification of patients to determine suitability for
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targeted treatments. These include tamoxifen, an ER modulator,
and trastuzumab (Herceptin), a monoclonal antibody targeting
the HER2 receptor, which are first-line therapies for ER+ tumors
in pre-menopausal women and HER2+ tumors, respectively.
Due to the availability of effective treatment options, hormone
receptor positive breast cancers generally have a better prognosis
(Fallahpour et al., 2017). Prior to the advent of modern therapies,
HER2+ patients had a worse prognosis. However, since the
introduction of HER2-targeted therapies, such as trastuzumab,
there has been a significant improvement in prognosis (Slamon
et al., 2001). Conversely, TNBCs (i.e., negative for all three
hormone receptors) still lack targeted treatments and continue
to have a comparatively poor prognosis (Dent et al., 2007;
Onitilo et al., 2009).
For tumors that are susceptible to targeted therapies various
therapies are available (Lumachi et al., 2013; Fallahpour et al.,
2017). For hormone receptor-positive cancers, these include
selective ER modulators, inhibitors of the aromatase enzyme
and antigonadotropic therapies. Patients with HER2+ tumors
also benefit from the availability of the monoclonal antibodies
trastuzumab and pertuzumab, which function by preventing
HER2 from functioning by inhibiting HER2-associated signaling
(Molina et al., 2001; Agus et al., 2002; Franklin et al., 2004; Junttila
et al., 2009). For tumors that are unsuitable for targeted therapies
(i.e., TNBC), treatment involves chemotherapy in combination
with radiotherapy and/or surgery (Foulkes et al., 2010; Wahba
and El-Hadaad, 2015). Chemotherapeutic agents that are
currently approved for use in breast cancer therapy typically
target DNA synthesis and repair pathways and tend to have more
serious side effects. Mechanistically, these therapies comprise
alkylating agents that irreversibly crosslink DNA and lead to
apoptosis (Hall and Tilby, 1992) [cyclophosphamide, mitomycin
C (Tomasz, 1995)]; inhibitors of DNA biosynthesis enzymes
such as dihydrofolate reductase [methotrexate (Goodsell, 1999)],
thymidine synthase [fluorouracil (Longley et al., 2003)] and
type II topoisomerase [mitoxantrone (Fox, 2004)]; or DNA
intercalators that inhibit DNA and RNA synthesis [epirubicin,
doxorubicin (Gewirtz, 1999)] (Figure 1A). Cytoskeletal drugs are
also approved for use in breast cancer therapy (e.g., paclitaxel)
and block cell cycle progression by stabilizing microtubule
polymers (Horwitz, 1994; Figure 1B).
In hormone receptor and/or HER2+ positive tumors, it
appears that much efficacy is derived from the availability
of therapies targeting protein-protein interactions (PPIs) that
drive disease. These therapies, which include tamoxifen,
anastrozole and trastuzumab, either directly or indirectly
block interactions between growth factors and their receptors.
However, due to the lack of actionable receptors in TNBC,
chemotherapy remains the first-line standard of care in
combination with radiotherapy and/or surgery. It is apparent that
these non-targeted chemotherapeutic agents represent generic
therapeutic strategies that broadly target cancerous tissues,
as they preferentially target rapidly dividing cells such as
those found in tumors. However, normal cells that divide
rapidly such as those in the digestive tract, hair follicles,
and bone marrow are also highly susceptible to cytotoxicity,
which leads to common chemotherapeutic side effects such
as mucositis, alopecia, and myelosuppression with subsequent
immunosuppression (Partridge et al., 2001). As a result, there is
a clear clinical need for the identification of actionable targets in
TNBC that can be used as the basis for the production of new
and more targeted therapies. It is likely that, to ensure specificity
in targeting, the identification of PPIs or protein networks that
drive disease will be necessary for this purpose.
A promising example of this concept is the inhibition of
interactions that induce immune tolerance such as the PD-1/PD-
L1 axis (Gatalica et al., 2014), inhibition of which promotes
T-cell proliferation, survival and cytotoxicity (Figure 1A). Most
recently this has included the approval of atezolizumab, an
anti-PD-L1 antibody, in combination with chemotherapy for
the treatment of PD-L1+ metastatic TNBC by the US FDA
in March 2019 (Schmid et al., 2018; Dolgin, 2019). Another
example is the recent use of poly ADP ribose polymerase
(PARP) inhibitors for the treatment of BRCA1-mutated tumors.
Although there continues to be a lack of targeted treatment
options for TNBC patients, ∼15% of TNBC tumors are driven
by germline mutations within the BRCA1 and BRCA2 genes
(Engel et al., 2018). These mutations result in defective double-
strand DNA repair machinery and lead to the accumulation
of DNA damage. PARP is another DNA repair protein that is
crucial for the repair of single-strand DNA breaks (Audebert
et al., 2004; Heale et al., 2006), which can develop into double-
strand breaks (DSBs) if not repaired before the initiation of DNA
replication (Farmer et al., 2005). In this context, BRCA1/BRCA2
mutated tumors cannot repair these DSBs, ultimately resulting in
cell death, whereas normal cells can compensate for the loss of
PARP function (Farmer et al., 2005). As a result, patients with
mutated BRCA1/BRCA2 are suitable candidates for additional
treatment with PARP inhibitors, such as the recently approved
drug olaparib which was approved in 2019 in Europe for germline
BRCA1/2-mutated HER2− breast cancer (Griguolo et al., 2018;
Le and Gelmon, 2018). However, this therapy class is only suitable
for patients with BRCA-mutated tumors and there is still intense
interest in the identification of the molecular drivers of TNBC.
MOLECULAR PROFILING OF BREAST
CANCERS FOR TARGET
IDENTIFICATION
Much effort has been invested into the molecular profiling of
breast cancers for the identification of novel drivers in TNBC
pathogenesis and to better define breast cancer subtypes. The first
of these classification models, proposed by Sørlie et al. (2003),
was based on the transcriptomic profiling of 115 malignant breast
tumors and identified five intrinsic subtypes of breast cancers
(Sørlie et al., 2001, 2003). Although the identification of these
intrinsic subtypes has provided much insight into breast cancer
biology, attempts to define possible somatic drivers of breast
cancer subtypes has remained difficult due to the heterogeneity
of the disease as well as a lack of clear driver mutations. More
recent work has aimed to tackle this issue by integrating genomic
and transcriptomic breast cancer data in much larger patient
sizes, a prime example of which is the recent METABRIC
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FIGURE 1 | An overview of current and emerging agents for TNBC therapy. (A) TNBC therapies targeting the cell surface and cytoplasm. Cell surface therapies
include inhibitors of immune tolerance inducing proteins such as PD1 and PD-L1. Cytoplasmic therapies include inhibitors of the Ras/MAPK pathway, especially
MEK inhibitors, inhibitors of the PI3K/AKT/mTOR pathway, inhibitors of the Hedgehog signaling pathway, and cell cycle inhibitors such as paclitaxel and CDK
inhibitors. (B) TNBC therapies targeting the nucleus. These therapies tend to target DNA synthesis and repair pathways or affect DNA viability to induce cell-cycle
arrest and cell death.
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dataset. This work characterized the genomic and transcriptomic
architecture of 2000 breast tumors (Curtis et al., 2012) and
resulted in the identification of 10 novel molecular subgroups,
known as integrative clusters, which are clustered according
to copy number alterations and gene expression data (Dawson
et al., 2013). Crucially, each integrative cluster is associated with
distinct clinical features and outcomes (Dawson et al., 2013). In
addition, the clusters have identified heterogeneity within tumors
classified according to receptor status and divided all previously
identified intrinsic subtypes into separate groups. Additional
transcriptomic studies have further highlighted the heterogeneity
of TNBC, which include studies by Lehmann et al. (2011, 2016)
and Burstein et al. (2015), both of which identified four molecular
subtypes of TNBC. As a result, breast cancer classification is now
evolving to describe a number of distinct molecular subgroups
based on multiple genomic factors, which has produced more
robust patient classifiers and is leading to a new stratification and
treatment paradigm for breast cancer patients. However, despite
this progress in the molecular characterization of TNBC, these
tumors remain to be mostly characterized by TP53 alterations
and copy number alterations involving 5q loss and gains at 8q,
10p and 12p (Dawson et al., 2013).
A limited number of studies have therefore attempted to
investigate the mutational landscape in TNBC, which has
mostly identified that TNBC is characterized by a low rate of
activating point mutations in common oncogenes, as well as
extensive individually rare mutations in other genes (Shi et al.,
2018). However, TNBCs appear to be particularly enriched for
alterations in tumor suppressor proteins, such as TP53, RB1, and
PTEN, as well as oncogenic alterations in the PI3K/AKT pathway
(Curtis et al., 2012; Koboldt et al., 2012). Regardless, common
TNBC “oncogenes” such as PIK3CA and other actionable targets,
such as the Ras/MAPK (Balko et al., 2013), JAK/STAT (Marotta
et al., 2011), Wnt (DiMeo et al., 2009), TGF-β (Bhola et al.,
2013), Hedgehog (Liu et al., 2006), and Notch (Harrison et al.,
2010) pathways, are all critical genes/signaling pathways in a wide
range cell types and contexts. As a result, any therapies designed
against these pathways are highly likely to result in off-target
cytotoxicity. Overall therefore, genome-wide studies have failed
to identify driving mutations distinct from those affecting TP53,
PIK3CA, and PTEN (Peluffo et al., 2019), and new therapeutic
angles are required to define better and more specific targets for
the production of TNBC therapies. One such angle to consider is
that alterations in epigenetics and transcriptional machinery may
be largely contributing to the transcriptional dysregulation seen
in TNBC malignancies.
TRANSCRIPTION FACTOR TARGETING
FOR POTENTIAL ENHANCED
THERAPEUTIC SPECIFICITY
Downstream effectors of traditionally targeted pathways, namely
transcription factors (TFs) involved in normal cellular function,
are often those subjected to dysregulation resulting in cancer
(Bass et al., 2009). Indeed, many cancer-related events either
directly involve TFs or indirectly modulate TF activity. This
highlights targeting TFs as a promising anticancer strategy
and as potentially superior therapeutic targets compared to
upstream signaling proteins and kinases (Konstantinopoulos and
Papavassiliou, 2011). Our progression in understanding of the
mechanistic properties of TFs and their associated networks, in
both diseased and normal cells, has created huge potential for
precision medicine in cancer. For example, targeting oncogenic
TFs may lead to preferential cancer cell death in tumors that
display TF dependency, whereas normal cells may be more
likely to tolerate a loss of TF function due to redundancies
in normal signaling pathways. One such case is the TRPS1
TF, which demonstrates breast lineage-specific transcriptional
dependency, likely due to lineage-restricted expression (Witwicki
et al., 2018). As a result, breast cancer cells lines display
sensitivity to TRPS1 shRNA targeting compared to cell lines
derived from colon, neuroblastoma, leukemia, prostate, and
rhabdoid tumors (Witwicki et al., 2018). TFs in this context
are therefore likely to have a high therapeutic potential, owing
to their critical role in tumor pathogenesis along with their
dispensability for physiologic cell function. Accordingly, many
studies have tried to capture the transcriptional landscape of
TNBC, thus identifying highly expressed genes and TFs that
may be liable to therapeutic targeting. However, TFs have
long been considered “undruggable” targets, which may result
from the large interaction surface areas used by TFs for
protein-DNA and PPIs as well as their predominant nuclear
localization, which makes them less accessible to therapeutic
agents (Yan and Higgins, 2013).
Despite these challenges, there are various opportunities
available for targeting TFs at different functional levels.
For example, TFs may be directly or indirectly targeted
through inhibition (or activation) at the expression level, at
the PPI level, at the post-translational modification level, at
the protein/DNA binding level, through the binding of a
small molecule in an inhibition/activation pocket or through
physical degradation (Figure 2). In addition, post-translational
modifications, which may result in context-specific PPIs and/or
differential assembly of epigenetic remodeling complexes,
must also be considered. To date, over 450 unique protein
modifications have been described, including phosphorylation,
acetylation, ubiquitination, methylation, and SUMOylation,
which can alter target protein activity, intracellular distribution,
protein interactions and protein longevity (Venne et al., 2014).
For phosphorylation alone, there are over 500 different kinases
in mammals (Woolfrey and Dell’Acqua, 2015), some of which
could conceivably be expressed in a tissue-specific manner and
may therefore give rise to differing versions of the same proteins
in various tissues.
Like all other cellular proteins, TF expression is controlled
by transcriptional activators and repressors (such as other TFs
or itself in a feedback loop) as well as by epigenetic machinery.
Aberrant activity of these processes may therefore result in
oncogenic transcriptional programs. For example, oncogenic
gene translocation and consequent juxtaposition of the c-MYC
gene with enhancer elements has been reported in multiple
myeloma, which may enhance c-MYC expression (Shou et al.,
2000), and aberrant expression of the HOXA cluster of TFs
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FIGURE 2 | Potential mechanisms of transcription factor (TF) targeting for cancer therapy. (A) Inhibition of oncogenic TF expression. This may take the form of
altering chromatin accessibility, through inhibitors of epigenetic machinery, or by disrupting the assembly of transcriptional machinery at the protein-protein or
protein-DNA binding level. (B) Depletion of oncogenic proteins by PROTAC-mediated proteasomal degradation. A bi-functional molecule containing a protein of
interest-binding region and an E3-ligase binding region links the protein of interest to an E3-ligase, leading to ubiquitination and proteasomal degradation.
(C) Inhibition of TF function through modulation of post-translational modifications. Assembly of oncogenic transcriptional (or epigenetic) assemblies may rely on
post-translational modifications. Inhibiting the enzymes responsible for these modifications or inhibiting the binding pocket of the specific modification may represent
feasible options for preventing the assembly of oncogenic transcriptional assemblies. (D) Inhibition of mutation-dependent transcriptional assemblies. Structural
information regarding the binding interfaces of mutated transcriptional or epigenetic proteins may allow for the design of therapies that inhibit mutation-dependent
interactions and prevent the assembly of mutation-dependent transcriptional machinery.
has been reported in several aggressive acute leukemias as a
result of oncogenic rearrangements of the MLL1 gene, a histone
methyltransferase (Kawagoe et al., 1999; Guenther et al., 2005).
More specifically, rearrangements of the MLL1 gene can lead to
the production of over 70 in-frame oncogenic fusion proteins,
which can add functionality by enabling interactions with histone
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methyltrasferases such as DOT1L (Krivtsov et al., 2007) or
may direct the MLL complex to unintended genomic areas,
resulting in an aberrant transcriptional program. Therapies have
been designed for both of these contexts, typically through
regulation at the epigenetic level. For example, HDAC and
histone methyltransferase inhibitors (e.g., against DOT1L), both
of which associate with the MLL complex, have entered clinical
trials for acute myeloid leukemia (Daigle et al., 2011; Chen
et al., 2013; Fredly et al., 2013; Morabito et al., 2016), whereas
negative regulation of oncogenic c-MYC has been achieved, for
example, by inhibitors of BRD4 (such as JQ1) which displace
BRD4 from the c-MYC promoter (Fowler et al., 2014). Control
of HOXA expression has also been attempted through disruption
of the MLL complex, for example by inhibiting the incorporation
of WDR5 into the MLL complex which is required for the
enzymatic activity of MLL1 (Li et al., 2016; Karatas et al.,
2017). These examples represent indirect TF targeting at the
epigenetic and PPI levels.
As well as indirect inhibition of TF function, direct inhibition
of TF interactions may be an attractive therapeutic approach.
Targets in this case may include single TF homodimers, a specific
heterodimeric TF pair or a multimeric transcriptional complex.
Indeed, TFs have the potential to form a large number of dimeric
structures with distinct biological properties (over 500 dimers
in human and up to 2500 dimers when considering alternate
splicing) that can allow for elaborate fine-tuning of responses
(Amoutzias et al., 2008). The concentration of each monomer
in the cell, its post-translational modifications and its binding
affinity for other monomers all play a role in determining dimer
formation and, consequently, will determine which signaling
process will dominate. These regulatory mechanisms therefore
offer multiple levels of complexity and likely represent an
underexploited therapeutic opportunity, as targeting specific TF
dimers or specifically modified TFs (e.g., phosphorylated at a
specific position) may offer exquisite therapeutic specificity. This
may become a viable approach through the identification of TF
states that contribute toward disease pathogenesis, especially as
TFs have traditionally been considered undruggable.
A good example of this concept is the Myc-Max and Mad-Max
heterodimerization system, whereby Max is a ubiquitous protein
that can heterodimerize with either Myc or Mad (Grandori
et al., 2000; Lüscher, 2001). Similarly, Myc and Mad can only
heterodimerize with Max, but not each other. Upon formation
of the Myc-Max heterodimer, recruitment of the mSWI/SNF
nucleosome remodeling complex or histone acetyltransferases
(HATs) occurs at the promoters of target genes, resulting in
transcriptional activation. Conversely, formation of the Max-
Mad heterodimer leads to recruitment of HDACs, which results
in silencing of target genes and is antagonistic to the Myc-
Max heterodimer. As a result, variations in the concentrations
or affinity of these complexes can lead to a transcriptional
bias and potentially alter the oncogenic capacity of the cell. As
previously discussed, post-translational modifications may offer
an additional level of complexity and can determine the transition
to a functional dimeric TF pair. This has been observed through
the phosphorylation of STAT proteins (Levy and Darnell, 2002) as
well as ReIB, which leads to the formation of p100-ReIB dimers
(Maier et al., 2003). Another example is the phosphorylation
of the bHLH protein E47, which blocks formation of the
homodimer and favors formation of a heterodimer with MyoD,
leading to the activation of muscle-specific transcriptional
activity (Lluís et al., 2005). It is therefore feasible to suggest that
phosphorylated versions of TFs that participate in oncogenic
interactions or transcriptional programs may represent attractive
therapeutic targets in the future, especially if the phosphorylated
protein does not exist or is very rare in healthy tissues.
TARGETING PROTEIN NETWORKS AND
CHROMATIN RE-MODELERS
In addition to TFs, it is important to consider the role played
by chromatin modulators in driving transformation. Mutated
protein members “hijack” remodeling machinery to localize
in different areas of the genome, leading to aberrant gene
expression. Although TFs in cancer are undoubtedly important,
open chromatin is more likely to facilitate gene expression.
Therefore, the targeting of PPIs specific to oncogenically
activated chromatin modulators may offer a more viable method
to silence dysregulated transcription in cancer. One clear example
is the BAF or mSWI/SNF complex, where genes encoding
subunits or associated proteins are mutated in over 20% of
cancers (Pierre and Kadoch, 2017). Such a high frequency of
mutations correlated with specific oncogenic phenotypes can be
attributed to a high degree of genetic non-redundancy within the
complex. An example is SMARCB1 inactivation in early pediatric
rhabdoid tumors, which is considered the sole genetic driving
event in an otherwise genomically stable malignancy (Wang
et al., 2017). Such stability is indicative of epigenetic changes
caused by an oncogenically activated BAF complex. The loss of
SMARCB1 reduces levels of the BAF complex, impairing normal
function and transcriptional homeostasis. Subsequent alteration
in genome-wide targeting reduces BAF binding to typical
enhancers required for transcription of cell differentiation genes.
Instead, remaining SMARCB1-deficient complexes maintain
binding at super enhancers, causing preferential transcription
of genes required for current cell identity maintenance, which
may be due to higher affinity BAF complex binding at these
sites. When specific proliferative progenitor cells are affected,
cells are effectively locked into a highly proliferative and
lowly differentiated state due to impaired enhancer targeting
working to drive oncogenic transformation (Wang et al., 2017).
Expression of another subunit of the complex, ARID1A, is
lost in colon cancer in mice causing a similar reduction
in levels of the BAF complex (Mathur et al., 2017). This
causes its absence at thousands of enhancers and subsequent
reduction/change in gene expression. ARID1B has a similar
binding preference and can compensate to some extent by
binding in the place of ARID1A, but the presence of this altered
complex causes extensive dysregulation of gene expression. This
further highlights the importance of complex composition and
the non-redundant nature of PPIs within this complex. There
are therefore a great many potential targets for therapy within
the BAF complex. Indeed, comprehensive understanding of
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the relationships between biochemistry and function must be
reached in order to unlock their greatest potential.
Another emerging field for PPI targeting is the modulation
of the ubiquitin pathway. For example, proteasome-mediated
degradation can be biased toward the preferential break down of
tumor suppressors and the apparent preservation of oncoproteins
in cancer cells (Wertz and Wang, 2019). As the process is a
cascade, there are several proteins which offer valuable targets
for anticancer therapies. There are three classes of enzymes
responsible for ubiquitination, E1, E2, and E3, which comprise
2, 40, and over 600 isozymes in humans respectively (Li
et al., 2008; Deshaies and Joazeiro, 2009; Schulman and Wade
Harper, 2009). Although it has been possible to modulate
the E1 and E2 members of the ubiquitination pathway, E3
enzymes have higher substrate specificity and offer greater
potential for specific targeting. One of the most notable E3
PPIs for targeting is the MDM2:p53 interaction, where MDM2
is the negative regulator for p53 and therefore an important
oncoprotein. Another method of modulation involving target
proteins and E3 enzymes are Proteolysis targeting chimeras
(PROTACs) (Sakamoto et al., 2001). PROTACs contain two
moieties which independently bind a relevant target protein
and an E3 ubiquitin ligase (Figure 2B). This brings the target
into close proximity for ubiquitination by the E3 enzyme and
marks the protein for degradation by the proteasome. This
system has the advantage of being able to target proteins such
as TFs, as PROTACs require only transient drug-target binding,
whilst not inhibiting substrate activity. The ubiquitin pathway
therefore offers an attractive therapeutic angle to the targeting
of TFs, helping to modulate proteins which are otherwise
difficult to mark.
It is clear that the wealth of existing proteomics data
needs to be harnessed to address this area, looking at
the specific interactions and phosphorylation states of
putative TNBC oncogenes in disease contexts versus those
observed in healthy tissue. This may take the form of
targeted approaches using emerging techniques such as rapid
immunoprecipitation mass spectrometry of endogenous proteins
(RIME) (Mohammed et al., 2016) or co-immunoprecipitation
coupled with mass spectrometry for the identification of PPIs
and the analysis of post-translational modifications. However,
unbiased and high-throughput approaches to investigate
interactions and post-translational modifications in a whole-
cell format are still lacking and therefore knowledge of
particular TNBC oncoproteins is currently required to take
this approach. The emerging field of single cell proteomics
may offer the opportunity to perform unbiased screens to
correlate particular protein states with cellular phenotypes
in the future but, as of yet, high-throughput single-cell
proteomics methods are not available for this purpose (Marx,
2019). However, the rate with which the single cell field is
progressing bodes well for this technology and no doubt
its development will offer unprecedented insight into PPIs
driving malignancy. The combination of the above approaches
may provide new therapeutic angles for the development of
novel, more targeted and more effective TNBC therapies, as
well as providing valuable insights into the mechanism of
TNBC pathogenesis.
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